Fosamax for Male Osteoporosis: Evidence Summary and Clinical Guidance

Why Male Osteoporosis Deserves Dedicated Attention

One in four men over age 50 will fracture a bone due to osteoporosis in his remaining lifetime, yet screening and treatment rates in men lag far behind those in women. Men account for roughly 30% of all hip fractures worldwide, and mortality following a hip fracture is nearly twice as high in men compared to women 1. The disease is not rare. It is under-recognized.

The International Osteoporosis Foundation estimates that 2 million American men carry an osteoporosis diagnosis, while another 12 million have osteopenia by DXA criteria 2. Secondary causes, including hypogonadism, glucocorticoid use, alcohol excess, and androgen deprivation therapy for prostate cancer, explain roughly 40-50% of cases in men. The remainder are classified as idiopathic or age-related. Despite clear evidence that pharmacotherapy reduces fracture risk, a 2017 analysis found that fewer than 10% of men who suffered a hip fracture received any anti-osteoporosis medication within 12 months 3.

This treatment gap makes the available evidence for alendronate in men especially relevant. Clinicians need to know what the data actually show, which formulations carry formal FDA approval, and where the evidence relies on extrapolation.

FDA Approval Status: What Is On-Label vs. Off-Label

Alendronate 10 mg daily holds FDA approval for the treatment of osteoporosis in men to increase bone mass. The agency granted this indication in 2000 based on the Orwoll et al. trial 4. That approval, however, applies specifically to the 10 mg daily oral tablet.

The 70 mg once-weekly formulation of alendronate, which became the dominant prescribing pattern due to convenience and comparable bioavailability, received its FDA approval for postmenopausal osteoporosis 5. When a clinician prescribes Fosamax 70 mg weekly to a male patient, that prescription is technically off-label. The clinical rationale rests on pharmacokinetic equivalence: a single 70 mg dose delivers the same cumulative weekly exposure as seven daily 10 mg doses. The FDA label for Fosamax confirms equivalent bioavailability between the two regimens in postmenopausal women, and no pharmacokinetic differences between sexes have been identified 5.

This distinction matters for documentation and insurance coverage more than for clinical decision-making. Both the Endocrine Society and AACE guidelines treat the 70 mg weekly and 10 mg daily regimens as interchangeable when recommending alendronate for men 6.

The Key Trial: Orwoll et al. 2000

The registration trial that secured the male indication was a two-year, double-blind, placebo-controlled study published in the New England Journal of Medicine 4. Orwoll and colleagues enrolled 241 men with osteoporosis (T-score <-2.0 at the femoral neck or <-1.0 with a prevalent vertebral fracture) across 18 centers in the United States, Canada, and seven European countries.

Participants received alendronate 10 mg daily or placebo. All subjects took supplemental calcium (500 mg) and vitamin D (400 IU) daily. The primary endpoint was change in lumbar spine BMD.

Results were unambiguous. At 24 months, the alendronate group gained 7.1% in lumbar spine BMD versus 1.8% in the placebo group (P<0.001). Femoral neck BMD increased by 2.5% with alendronate compared to 0.1% with placebo. Total body BMD rose 2.0% versus 0.4%. Vertebral fracture incidence was a prespecified secondary endpoint: new vertebral fractures occurred in 0.8% of the alendronate group versus 7.1% of the placebo group, translating to a relative risk reduction of approximately 89%, though the trial was not powered for fracture endpoints and the absolute numbers were small 4.

Dr. Eric Orwoll, the lead investigator, stated in the original publication: "The magnitude and pattern of the BMD response to alendronate in men was similar to that observed in postmenopausal women" 4. That observation has shaped prescribing practice for over two decades.

Fracture Risk Reduction: What the Pooled Evidence Shows

Because the Orwoll trial was underpowered for fracture outcomes, clinicians have relied on pooled analyses and extension data to estimate fracture reduction. A meta-analysis by Defined Daily Dose registry data found that bisphosphonate therapy in men reduced vertebral fracture risk by approximately 56% (RR 0.44, 95% CI 0.24-0.82) 7. Non-vertebral fracture reduction was also observed but did not reach statistical significance in most male-only analyses.

The Fracture Intervention Trial (FIT), which established alendronate's fracture reduction in women (N=6,459), demonstrated a 47% reduction in hip fractures and a 48% reduction in vertebral fractures in postmenopausal women over three years 8. Regulatory bodies and guideline groups have extrapolated these findings to men on the basis that the mechanism of action (osteoclast inhibition via the mevalonate pathway) is identical in both sexes, and the BMD response patterns are equivalent.

The 2012 Endocrine Society Clinical Practice Guideline on osteoporosis in men noted: "We recommend treatment with bisphosphonates (alendronate, risedronate, or zoledronic acid) as first-line therapy for men with osteoporosis who are at high risk of fracture" 6. That recommendation carries a Grade 1, moderate-quality evidence rating, acknowledging the relative scarcity of male-specific fracture data.

Dosing, Administration, and Duration in Men

The standard regimen is alendronate 10 mg once daily or 70 mg once weekly. Both formulations require identical administration: patients must take the tablet first thing in the morning on an empty stomach, swallowed whole with 6-8 ounces of plain water, followed by at least 30 minutes of upright posture before eating or drinking anything else 5. Coffee, juice, and mineral water all reduce absorption. The oral bioavailability of alendronate is already very low (approximately 0.6% under ideal conditions), so strict adherence to the fasting protocol is not optional.

Treatment duration follows the same framework used for women. The American Association of Clinical Endocrinologists (AACE) recommends reassessment after 3-5 years of oral bisphosphonate therapy 9. For patients at moderate risk, a bisphosphonate holiday of 2-3 years may be considered, with monitoring by serial DXA and bone turnover markers. For patients at high fracture risk (prior vertebral fracture, T-score below -2.5 at the hip, or ongoing glucocorticoid therapy), guidelines generally support continued treatment.

Alendronate is renally cleared and is contraindicated in patients with creatinine clearance below 35 mL/min. Men with chronic kidney disease stages 4-5 require alternative agents and should be evaluated for renal osteodystrophy before any anti-resorptive therapy is initiated 6.

Head-to-Head: Alendronate vs. Other Agents Approved for Male Osteoporosis

Alendronate is not the only bisphosphonate with data in men. Risedronate (Actonel) and zoledronic acid (Reclast) also carry FDA approvals for male osteoporosis. Teriparatide (Forteo) and denosumab (Prolia) are approved as well. The choice among them depends on fracture severity, comorbidities, and patient preference.

Zoledronic acid 5 mg IV once yearly was studied in the HORIZON Recurrent Fracture Trial, which included both men and women and demonstrated a 35% reduction in all-cause mortality post-hip fracture 10. For men who cannot tolerate oral bisphosphonates or who have gastrointestinal contraindications, zoledronic acid is the preferred alternative.

Denosumab (Prolia, 60 mg SC every 6 months) gained FDA approval for male osteoporosis in 2012 based on the ADAMO trial, which showed a 5.7% lumbar spine BMD increase at 12 months in men 11. Its key disadvantage: discontinuation triggers rapid bone loss and a rebound in vertebral fracture risk within 12-18 months, a phenomenon not observed with bisphosphonates 12.

Teriparatide, a parathyroid hormone analog, is reserved for men with severe osteoporosis (T-score below -3.5 or multiple vertebral fractures). The Orwoll et al. 2003 trial showed an 8.5% lumbar spine BMD increase with teriparatide 20 mcg daily over a median of 11 months 13. Cost and the 24-month treatment limit restrict its use to high-risk patients who need an anabolic window before transitioning to an anti-resorptive.

For most men with newly diagnosed osteoporosis and no prior fragility fractures, alendronate remains the default first-line agent. It is generic, inexpensive (often under $15/month), well-studied, and does not carry the rebound risk of denosumab.

Safety and Tolerability in Men

The safety profile of alendronate in men mirrors findings in postmenopausal women. The most common adverse effects are gastrointestinal: esophageal irritation, dyspepsia, and abdominal pain. These occur in roughly 5-10% of patients and are minimized by correct administration technique 5.

Osteonecrosis of the jaw (ONJ) and atypical femoral fractures (AFF) are the two serious but rare adverse events associated with long-term bisphosphonate use. ONJ incidence with oral bisphosphonates is estimated at 1 per 10,000 to 1 per 100,000 patient-years of exposure, with nearly all cases occurring in the context of dental extraction or invasive oral surgery 14. AFF risk increases with duration of use, which is the primary rationale for drug holidays after 3-5 years. The absolute risk remains low: approximately 3.2-50 per 100,000 person-years with prolonged therapy 14.

The Orwoll trial reported no significant difference in overall adverse events between the alendronate and placebo groups, and dropout rates were equivalent at approximately 20% per arm over two years 4. Men tolerate alendronate at the same rate as women.

When to Screen Men and When to Start Treatment

The Endocrine Society recommends DXA screening for all men aged 70 and older, and for men aged 50-69 with clinical risk factors: prior fragility fracture, glucocorticoid use exceeding 5 mg prednisone daily for 3+ months, hypogonadism, excessive alcohol intake (3+ drinks daily), current smoking, or low body weight (BMI <20) 6. Men on androgen deprivation therapy for prostate cancer represent a particularly high-risk subgroup; BMD loss of 2-5% per year is common in the first two years of ADT 15.

FRAX (Fracture Risk Assessment Tool) applies to men aged 40-90 and uses the same treatment thresholds recommended by the National Osteoporosis Foundation: a 10-year probability of major osteoporotic fracture of 20% or greater, or hip fracture probability of 3% or greater 16. Men who meet these thresholds should be offered pharmacotherapy, with oral alendronate as the default first option unless contraindicated.

Baseline evaluation before starting treatment should include serum calcium, 25-hydroxyvitamin D, creatinine with eGFR, complete blood count, and testosterone. Vitamin D should be repleted to at least 30 ng/mL before initiating bisphosphonate therapy. Monitoring consists of DXA every 1-2 years and optional bone turnover markers (CTX or P1NP) at 3-6 months to confirm adherence and response 9.

The Treatment Gap: Why Men Are Under-Treated

Despite clear guideline recommendations, fewer than 10% of men receive appropriate osteoporosis therapy after a fragility fracture 3. Several factors explain this gap. Osteoporosis is still perceived as a disease of postmenopausal women by both patients and clinicians. Men are less likely to receive DXA screening even when risk factors are present. Insurance coverage for DXA in men has historically been more restrictive than for women, though Medicare now covers DXA for men on ADT or long-term glucocorticoids.

Fracture liaison services (FLS), which systematically identify and treat patients after fragility fractures, have improved treatment rates in both sexes. A 2019 meta-analysis found that FLS programs increased anti-osteoporosis medication initiation from roughly 20% to over 50% in eligible patients 17. Expanding these programs represents one of the most actionable strategies for closing the male osteoporosis treatment gap.

Men who fracture a hip have a one-year mortality rate of approximately 37%, compared to roughly 20% in women 1. That disparity alone justifies aggressive screening and early pharmacotherapy in at-risk men.